CancerSEEK
CancerSEEK is a blood test (also called a liquid biopsy) designed to detect multiple types of cancer at the earliest stages possible, before noticeable symptoms occur.
CancerSEEK is being developed to combine cutting-edge liquid biopsy technology with a machine learning engine, which will enable the test to improve with every person that is screened. It is designed to be integrated into your routine medical care, alongside other existing cancer screening tools.
With the CancerSEEK test as our foundation, we are developing and building not just the test itself, but a comprehensive and integrated service that includes result interpretation, follow-up testing, confirmed cancer diagnosis and facilitation into oncology care. At Thrive Earlier Detection, we will be a partner for healthy patients, cancer patients and physicians throughout the entire journey.
Results From DETECT-A – The First Prospective, Interventional Study of a Blood-Based Multicancer Test
An early version of CancerSEEK developed in 2016 was evaluated in DETECT-A, a study of 10,006 women between the ages of 65 to 75 without a prior cancer history.
The results, published in Science in April 2020, demonstrated that our blood test more than doubled the number of cancers that were first detected through screening, identified 65% of cancers at earlier stages, and identified cancers across 10 organs, seven of which have no recommended standard-of-care tests.
Data from this study, along with other data and ongoing discussions with regulatory authorities, will help inform Thrive’s design of future studies, including those intended to support regulatory approvals.
Overview of the DETECT-A Data
CancerSEEK is currently in development and is not yet available to patients. Information about enrolling in upcoming clinical trials will be provided in the future.
Publications
April 28, 2020
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
Published in Science. To request a copy of this publication, please contact publications@thrivedetect.com.
NOTE: The upload of the supporting raw data to the European Genome-phenome Archive (Study Accession ID EGAS00001004372) is in progress and expected to be completed by the end of the calendar year. In the interim, the data can be made available to investigators requiring urgent access by contacting either of the following co-authors: Ken Kinzler (kinzlke@jhmi.edu) or Isaac Kinde (publications@thrivedetect.com).
February 23, 2018
Detection and localization of surgically resectable cancers with a multianalyte blood test
Published in Science
February 23, 2018
Detection and localization of surgically resectable cancers with a multianalyte blood test
Published in Science Supplement